Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00513851 · ClinicalTrials.gov registry record · Phase 1

Phase 1 Study of OSI-930 in Cancer Patients

A Phase 1 study of Advanced Solid Tumors, sponsored by Astellas Pharma.

Completed
Registry status
Phase 1
Development phase
60
Enrollment target
3
Study locations

NCT00513851 is a Phase 1 study of Advanced Solid Tumors that has completed, run by Astellas Pharma. The registered enrollment target is 60 participants, below the 198-participant average among 144 other Advanced Solid Tumors trials with a reported enrollment target (70% lower). The trial reports 3 study locations across 3 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00513851, a Phase 1 study of Advanced Solid Tumors, has completed, sponsored by Astellas Pharma.

COMPLETED
Registry status
Phase 1
Development phase
60 participants
Enrollment target
3
Study locations

Study Summary

Open label, phase 1, dose escalation

Conditions Studied

Advanced Solid Tumors

Interventions

  • DRUG OSI-930

Study Locations (3)

Colorado

  • University of Colorado Cancer Center - Aurora

Massachusetts

  • Dana-Farber Cancer Institute - Boston

Surrey

  • Cancer Research UK Professor of Medical Oncology - Sutton

Trial Details

FieldValue
Enrollment Target 60 participants
Start Date 2006-04
Est. Completion 2009-09
Phase Phase 1

Sponsor

Astellas Pharma

165 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT00513851

The ClinicalTrials.gov registry entry for NCT00513851 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 60 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 198-participant average among 144 other Advanced Solid Tumors trials with a reported enrollment target (70% lower). The listed sponsor is Astellas Pharma, which has 165 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Advanced Solid Tumors appearing as the primary indexed condition, and to 1 intervention - of which OSI-930 is the first listed.

NCT00513851 reports 3 study locations spanning 3 distinct geographic areas - top geographies include Colorado, Massachusetts, Surrey.

Frequently Asked Questions

What is clinical trial NCT00513851 about?

NCT00513851 is a clinical study titled "Phase 1 Study of OSI-930 in Cancer Patients". Open label, phase 1, dose escalation

What is the current status of trial NCT00513851?

This trial is currently completed. It is a Phase 1 study. The enrollment target is 60 participants. The study started on 2006-04. Estimated completion is 2009-09.

What conditions does trial NCT00513851 study?

This clinical trial studies the following conditions: Advanced Solid Tumors.

What interventions are being tested in trial NCT00513851?

The interventions under investigation include: OSI-930 (DRUG).

Who is sponsoring clinical trial NCT00513851?

This trial is sponsored by Astellas Pharma, which has 165 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT00513851 being conducted?

This trial has 3 study locations across Colorado, Massachusetts, Surrey. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Advanced Solid Tumors

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Advanced Solid Tumors

All registered trials for this condition

Colorado

All trials with a study site in Colorado

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.